Related Experiment Video
Updated: Mar 6, 2026
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Hashrul Rashid1, Ian T Meredith1, Arthur Nasis1
1Monash Cardiovascular Research Centre, MonashHEART, Monash Health and Monash University Department of Medicine (MMC), Melbourne, Vic, Australia.
Insights
New PCSK9 inhibitors offer significant LDL-C reduction beyond statins for cardiovascular disease patients. Further trials are needed to confirm their long-term benefits and address cost concerns before widespread adoption.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Cardiovascular disease is a leading cause of death, with high LDL-C as a key risk factor.
- Statins are effective but insufficient for some patients due to efficacy or intolerance.
- Novel treatments are needed for patients with elevated LDL-C and coronary atherosclerosis.
Purpose of the Study:
- To review the development and clinical efficacy of PCSK9 inhibitors.
- To assess PCSK9 inhibitors in specific patient populations.
- To highlight future research directions and challenges for PCSK9 inhibitor adoption.
Main Methods:
- Literature review of studies on PCSK9 inhibitor development and clinical trials.
- Analysis of efficacy data in various patient groups.
- Discussion of safety, cost, and future research needs.
Main Results:
- PCSK9 inhibitors significantly lower LDL-C, exceeding statin effects.
- Evidence supports efficacy in specific patient groups, including statin-intolerant individuals.
- Morbidity and mortality benefits are not yet established, and concerns about adverse effects and cost exist.
Conclusions:
- PCSK9 inhibitors represent a promising new class of lipid-lowering therapy.
- Further research is essential to demonstrate long-term cardiovascular outcomes and cost-effectiveness.
- Addressing safety and economic factors is crucial for integrating PCSK9 inhibitors into clinical practice.
Abstract:
Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations, with elevated low-density lipoprotein-cholesterol (LDL-C) levels being a major modifiable risk factor for coronary atherosclerosis. While lipid-lowering therapies such as statins are effective in lowering LDL-C, a proportion of patients do not achieve target LDL-C goals with statins or are intolerant to statins necessitating other treatment options. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of agents that reduce LDL-C beyond the maximum achievable LDL-C reductions with statins, and have been well studied in different patient groups. However, there are concerns regarding their potential adverse effects and cost, given that morbidity and mortality benefits have not yet been demonstrated. This state-of-the art review provides an overview of the development of PCSK9 inhibitors, the evidence regarding their clinical efficacy in specific target populations, and highlights future trials and challenges that need to be addressed before PCSK9 inhibitors are widely adopted into contemporary clinical practice.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers